首页> 中国专利> 一种用于促进骨髓间充质干细胞成骨分化的基因抑制剂

一种用于促进骨髓间充质干细胞成骨分化的基因抑制剂

页面导航

摘要
著录项
相似文献

摘要

本发明公开了一种用于促进骨髓间充质干细胞成骨分化的基因抑制剂。所述的基因抑制剂为LINC01877的shRNA。通过ALP酶活性检测，茜素红染色，实时荧光定量RCR和Western Blot本发明证明LINC01877基因抑制剂能够存进骨髓间充质干细胞的ALP酶活性，钙化水平，成骨分化相关基因RUNX2、ALP和OCN基因的mRNA水平和蛋白水平表达，因此，LINC01877基因抑制剂可以用于制备骨髓间充质干细胞的成骨分化促进剂来促进骨髓间充质干细胞的成骨分化。

著录项

公开/公告号CN111849993A

专利类型发明专利
公开/公告日2020-10-30

原文格式PDF
申请/专利权人山东殷氏干细胞有限公司;
展开▼

申请/专利号CN202010837292.X
发明设计人马真艳;
展开▼

申请日2020-03-18
分类号C12N15/113(20100101);C12N5/077(20100101);
代理机构37231 济南智圆行方专利代理事务所(普通合伙企业);
代理人梁轶聪
地址 250013 山东省济南市历下区经十路9999黄金时代广场D座1606室
入库时间 2023-06-19 08:42:38

相似文献

专利
中文文献
外文文献

1. 一种用于促进骨髓间充质干细胞成骨分化的基因抑制剂 [P] . 中国专利： CN111849993B . 2022.01.14
2. 一种非编码RNA靶标及其抑制剂在制备促进骨髓间充质干细胞成骨分化的药物中的应用 [P] . 中国专利： CN107502586B . 2018.05.22
3. FOOD COMPOSITION FOR INCREASING MUSCLE MASS, MUSCLE MASS INCREASING AGENT, THERAPEUTIC AGENT FOR LOCOMOTIVE SYNDROME, THERAPEUTIC AGENT FOR SARCOPENIA, EXERCISE FUNCTION MAINTENANCE AGENT, MUSCLE ATROPHY-RELATED GENE EXPRESSION INHIBITOR, MUSCLE PROTEIN DEGRADATION INHIBITOR, MUSCLE ATROPHY PREVENTION AGENT, MUSCLE SYNTHESIS-RELATED GENE EXPRESSION PROMOTER, AND MUSCLE SYNTHESIS PROMOTER [P] . 世界知识产权组织专利： WO2019026930A1 . 2019-02-07

机译：用于增加肌肉质量的食物成分，用于肌肉活动障碍的肌肉质量增加剂，用于机车综合症的治疗剂，用于肌肉萎缩症的治疗剂，运动功能维持剂，与肌肉萎缩相关的基因表达抑制物，肌萎缩性肌病诱导因子抑制剂，肌肉萎缩抑制剂基因表达促进剂和肌肉合成促进剂
4. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
5. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症